Methylphenidate, an amphetamine-like psychomotor stimulant, alleviates fatigue in many patient populations and is recommended, and often prescribed offlabel, to improve fatigue in multiple sclerosis (MS). 1 Recent research also supports that methylphenidate can improve balance and walking in various populations, 2-4 but no published studies have evaluated the effects of repeated doses of methylphenidate on fatigue, balance, or walking in MS.
Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis Date received: 6 January 2017; accepted: 15 January 2017
Methylphenidate, an amphetamine-like psychomotor stimulant, alleviates fatigue in many patient populations and is recommended, and often prescribed offlabel, to improve fatigue in multiple sclerosis (MS). 1 Recent research also supports that methylphenidate can improve balance and walking in various populations, [2] [3] [4] but no published studies have evaluated the effects of repeated doses of methylphenidate on fatigue, balance, or walking in MS.
If effective for mobility and fatigue in MS, methylphenidate would provide an inexpensive (~US$15-US$20/month) option that could be administered at a range of doses to optimize effects. We therefore completed a 6-week, double-blind, randomized controlled trial pilot study to compare the effects of escalating doses of oral methylphenidate to matched placebo, on balance, walking, and fatigue in MS.
We recruited 24 people aged 20-65 years with MS, poor balance, and walking difficulties from the VA Portland Health Care System and the surrounding community. We excluded those taking methylphenidate, modafinil, or armodafinil and those with contraindications to methylphenidate. Participants presented for a baseline visit and three follow-up visits, each 2 weeks ± 2 days apart. They were randomly allocated in a 1:1 ratio to receive methylphenidate or placebo, with the dose escalating at each visit, from 10 mg b.i.d. to 20 mg b.i.d. to 30 mg b.i.d. Participants exited the study at 6 weeks or earlier for drug intolerance. At each visit, participants completed the Modified Fatigue Index Scale (MFIS), Activitiesspecific Balance Confidence (ABC) scale, Timed 25-Foot Walk (T25FW), and the oral Symbol Digit Modalities Test (SDMT), and we fit a Bayesian hierarchical model to the complete set of outcomes at each time point to estimate differences in outcomes between groups.
At baseline, groups were generally well matched. In general, average performance on all measures improved over time in both groups, with greater improvements in the placebo group than in the methylphenidate group at all doses ( Figure 1 ). The T25FW, MFIS, and SDMT showed at least 60% probability of a deleterious effect of methylphenidate compared to placebo at all doses. By the 30 mg b.i.d. dose, there is at least 80% certainty that methylphenidate was less beneficial than placebo for all outcomes. For the ABC there was, at best, no deleterious impact of methylphenidate at 10 mg b.i.d. and 20 mg b.i.d., but by 30 mg b.i.d., there was also a negative effect compared to placebo for this outcome.
There were similar adverse events (AEs) in both groups. The most common in both groups were typical for methylphenidate, including insomnia (six methylphenidate, four placebo) and gastrointestinal symptoms (three methylphenidate, four placebo). In the methylphenidate group, two exited after the 20 mg b.i.d. dose (one for escalating blood pressure and one for nightmares) and two exited during the 30 mg b.i.d. dose (one for insomnia and one for tachycardia). In the placebo group, two exited after the 10 mg b.i.d. dose (one for hypertension and one for a fall) and four exited during the 20 mg b.i.d. dose (two for hypertension, one for a family emergency, and one felt lightheaded). Adherence was high (94% for methylphenidate and 95% for placebo) and blinding was good (60% participants correct and 40% examiners correct).
Although limited by small sample size, this study suggests that methylphenidate at up to 60 mg daily, in divided doses, is no more effective than placebo for improving balance, walking, or fatigue in people with MS. The lack of benefit for balance and walking may be because methylphenidate is most likely to help balance and walking in MS by improving cognition, and cognition in this sample, as reflected by mean SDMT scores of around 50, was within normal range for age, limiting potential for improvement. The lack of benefit for fatigue is more concerning because study participants had severe fatigue (mean baseline MFIS score around 41-42) and therefore had potential to improve. If the lack of improvements with methylphenidate compared to placebo in this study accurately represents the effects in most people with MS, why is this medication recommended and used clinically? In our experience, people with MS who take methylphenidate commonly report feeling better. But, does this reflect activation and euphoria similar to that produced by other stimulants such D-amphetamine and cocaine.
Methylphenidate may make people feel good without actually improving MS-related fatigue.
Based on the results of this study, a full-scale trial to examine benefits of methylphenidate for fatigue, balance, or walking in MS is not recommended and, given the habit-forming potential of this medication, we recommend clinicians carefully assess the effectiveness of methylphenidate for the prescribed indication as distinct from other reasons patients may wish to take this drug.
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